Evaluating the Safety and effectivenesS in Adult KorEaN Patients Treated With Tolvaptan for Management of Autosomal domInAnt poLycystic Kidney Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

118

Participants

Timeline

Start Date

July 1, 2019

Primary Completion Date

May 25, 2022

Study Completion Date

May 25, 2022

Conditions
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions
DRUG

Tolvaptan

30mg and 15mg of Tolvaptan Tablet

Trial Locations (18)

Unknown

Inje University Busan Paik Hospital, Busan

Kosin University Gospel Hospital, Busan

Hallym University Chuncheon Sacred Heart Hospital, Chuncheon

Keimyung University Dongsan Medical Center, Daegu

Kyungpook National University Hospital, Daegu

Chungnam National University Hospital, Daejeon

Chonnam National University Hospital, Gwangju

Gachon University Gil Medical Center, Incheon

Hallym University Medical Center, Pyeongchon

Seoul National University Bundang Hospital, Seongnam-si

Gangnam Severance Hospital, Seoul

Hallym University Kangnam Sacred Heart Hospital, Seoul

Hanyang University Seoul Hospital, Seoul

Kangbuk Samsung Hospital, Seoul

Severance Hospital, Seoul

SMG-SNU Boramae Medical Center, Seoul

The Catholic University of Korea Seoul St. Mary's Hospital, Seoul

03080

Seoul National University Hospital, Seoul

All Listed Sponsors
lead

Korea Otsuka Pharmaceutical Co., Ltd.

INDUSTRY